FibroGen (FGEN) Stock Price Down 5.5%
FibroGen Inc (NASDAQ:FGEN)’s share price was down 5.5% on Thursday . The stock traded as low as $51.00 and last traded at $51.00. Approximately 592,641 shares changed hands during trading, a decline of 3% from the average daily volume of 608,035 shares. The stock had previously closed at $53.95.
Several equities analysts recently weighed in on FGEN shares. Mizuho reissued a “hold” rating and set a $61.00 price objective on shares of FibroGen in a research report on Thursday, November 9th. ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Four research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. FibroGen currently has an average rating of “Buy” and an average price target of $65.67.
The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. The firm has a market cap of $4,190.00, a PE ratio of -25.12 and a beta of 1.74.
In other FibroGen news, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $46.65, for a total value of $93,300.00. Following the completion of the transaction, the director now owns 24,000 shares of the company’s stock, valued at approximately $1,119,600. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Pat Cotroneo sold 2,851 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $46.00, for a total value of $131,146.00. Following the completion of the transaction, the vice president now directly owns 183,852 shares of the company’s stock, valued at approximately $8,457,192. The disclosure for this sale can be found here. Insiders have sold a total of 328,917 shares of company stock valued at $16,142,651 in the last three months. 13.60% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. grew its stake in shares of FibroGen by 95.0% in the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of FibroGen by 41.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 1,147 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of FibroGen in the 2nd quarter valued at approximately $237,000. 57.11% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2018/02/08/fibrogen-fgen-stock-price-down-5-5.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.